Pan-cancer Analysis of ASB3 and the Potential Clinical Implications for Immune Microenvironment of Glioblastoma Multiforme

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jan 9

PMID 36618381

Authors

Long Mu

Zhibin Han

Shengkun Yu

Aowen Wang

Dongjiang Chen

Sijia Kong

Yifei Gu

Lin Xu

Axiang Liu

Ruohan Sun

Yu Long

Affiliations

Soon will be listed here.

Abstract

Background: Ankyrin repeat and SOCS Box containing 3 (ASB3) is an E3 ubiquitin ligase. It has been reported to regulate the progression of some cancers, but no systematic pan-cancer analysis has been conducted to explore its function in prognosis and immune microenvironment.

Method: In this study, mRNA expression data were downloaded from TCGA and GTEx database. Next generation sequencing data from 14 glioblastoma multiforme (GBM) samples by neurosurgical resection were used as validation dataset. Multiple bioinformatics methods (ssGSEA, Kaplan-Meier, Cox regression analysis, GSEA and online tools) were applied to explore ASB3 expression, gene activity, prognosis of patients in various cancers, and its correlation with clinical information, immune microenvironment and pertinent signal pathways in GBM. The biological function of ASB3 in tumor-infiltrating lymphocytes (TILs) was verified using an animal model.

Results: We found that ASB3 was aberrant expressed in a variety of tumors, especially in GBM, and significantly correlated with the prognosis of cancer patients. The level of ASB3 was related to the TMB, MSI and immune cell infiltration in some cancer types. ASB3 had a negative association with immune infiltration and TME, including regulatory T cells (Tregs), cancer-associated fibroblasts, immunosuppressors and related signaling pathways in GBM. ASB3 overexpression reduced the proportion of Tregs in TILs. GSEA and PPI analysis also showed negative correlation between ASB3 expression and oncogenetic signaling pathways in GBM.

Conclusion: A comprehensive pan-cancer analysis of ASB3 showed its potential function as a biomarker of cancer prognosis and effective prediction of immunotherapy response. This study not only enriches the understanding of the biological function of ASB3 in pan-cancer, especially in GBM immunity, but also provides a new reference for the personalized immunotherapy of GBM.

Citing Articles

The E3 ligase ASB3 downregulates antiviral innate immunity by targeting MAVS for ubiquitin-proteasomal degradation.

Cheng M, Lu Y, Wang J, Wang H, Sun Y, Zhao W Cell Death Differ. 2024; 31(12):1746-1760.

PMID: 39266719 PMC: 11618372. DOI: 10.1038/s41418-024-01376-5.

ASB3 expression aggravates inflammatory bowel disease by targeting TRAF6 protein stability and affecting the intestinal microbiota.

Cheng M, Xu B, Sun Y, Wang J, Lu Y, Shi C mBio. 2024; 15(9):e0204324.

PMID: 39162488 PMC: 11389410. DOI: 10.1128/mbio.02043-24.

The prognostic and immune significance of C15orf48 in pan-cancer and its relationship with proliferation and apoptosis of thyroid carcinoma.

Li C, Tang Y, Li Q, Liu H, Ma X, He L Front Immunol. 2023; 14:1131870.

PMID: 36969231 PMC: 10033576. DOI: 10.3389/fimmu.2023.1131870.

References

Au V, Tsang F, Man K, Fan S, Poon R, Lee N . Expression of ankyrin repeat and SOCS box containing 4 (ASB4) confers migration and invasion properties of hepatocellular carcinoma cells. Biosci Trends. 2014; 8(2):101-10. DOI: 10.5582/bst.8.101. View

Chung A, Guan Y, Yuan Z, Albina J, Chin Y . Ankyrin repeat and SOCS box 3 (ASB3) mediates ubiquitination and degradation of tumor necrosis factor receptor II. Mol Cell Biol. 2005; 25(11):4716-26. PMC: 1140645. DOI: 10.1128/MCB.25.11.4716-4726.2005. View

Chen X, Song E . Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2018; 18(2):99-115. DOI: 10.1038/s41573-018-0004-1. View

Bader J, Voss K, Rathmell J . Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell. 2020; 78(6):1019-1033. PMC: 7339967. DOI: 10.1016/j.molcel.2020.05.034. View

Broekman M, Maas S, Abels E, Mempel T, Krichevsky A, Breakefield X . Multidimensional communication in the microenvirons of glioblastoma. Nat Rev Neurol. 2018; 14(8):482-495. PMC: 6425928. DOI: 10.1038/s41582-018-0025-8. View

Hu X, Wang J, Chu M, Liu Y, Wang Z, Zhu X . Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy. Mol Ther. 2021; 29(3):908-919. PMC: 7934629. DOI: 10.1016/j.ymthe.2020.12.032. View

Ru B, Wong C, Tong Y, Zhong J, Zhong S, Wu W . TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019; 35(20):4200-4202. DOI: 10.1093/bioinformatics/btz210. View

Lou W, Wang W, Chen J, Wang S, Huang Y . ncRNAs-mediated high expression of SEMA3F correlates with poor prognosis and tumor immune infiltration of hepatocellular carcinoma. Mol Ther Nucleic Acids. 2021; 24:845-855. PMC: 8121632. DOI: 10.1016/j.omtn.2021.03.014. View

Gao T, Liu Z, Wang Y, Cheng H, Yang Q, Guo A . UUCD: a family-based database of ubiquitin and ubiquitin-like conjugation. Nucleic Acids Res. 2012; 41(Database issue):D445-51. PMC: 3531133. DOI: 10.1093/nar/gks1103. View

10.

Moatti A, Debesset A, Pilon C, Beldi-Ferchiou A, Leclerc M, Redjoul R . TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation. J Immunother Cancer. 2022; 10(4). PMC: 8987798. DOI: 10.1136/jitc-2021-003508. View

11.

Jin W, Mao X, Qiu G . Targeting Deubiquitinating Enzymes in Glioblastoma Multiforme: Expectations and Challenges. Med Res Rev. 2016; 37(3):627-661. DOI: 10.1002/med.21421. View

12.

Fumet J, Truntzer C, Yarchoan M, Ghiringhelli F . Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. Eur J Cancer. 2020; 131:40-50. PMC: 9473693. DOI: 10.1016/j.ejca.2020.02.038. View

13.

Wang D, Ma L, Wang B, Liu J, Wei W . E3 ubiquitin ligases in cancer and implications for therapies. Cancer Metastasis Rev. 2017; 36(4):683-702. DOI: 10.1007/s10555-017-9703-z. View

14.

Du W, Lu Z, Ye W, Fu X, Zhou Y, Kuang C . The loss-of-function mutations and down-regulated expression of ASB3 gene promote the growth and metastasis of colorectal cancer cells. Chin J Cancer. 2017; 36(1):11. PMC: 5237493. DOI: 10.1186/s40880-017-0180-0. View

15.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

16.

Tan A, Ashley D, Lopez G, Malinzak M, Friedman H, Khasraw M . Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020; 70(4):299-312. DOI: 10.3322/caac.21613. View

17.

Zhang W, Liu F, Che Z, Wu M, Tang Z, Liu J . ASB3 knockdown promotes mitochondrial apoptosis via activating the interdependent cleavage of Beclin1 and caspase-8 in hepatocellular carcinoma. Sci China Life Sci. 2019; 62(12):1692-1702. DOI: 10.1007/s11427-018-9505-0. View

18.

Dawson J, Serrels A, Stupack D, Schlaepfer D, Frame M . Targeting FAK in anticancer combination therapies. Nat Rev Cancer. 2021; 21(5):313-324. PMC: 8276817. DOI: 10.1038/s41568-021-00340-6. View

19.

Tanaka A, Sakaguchi S . Regulatory T cells in cancer immunotherapy. Cell Res. 2016; 27(1):109-118. PMC: 5223231. DOI: 10.1038/cr.2016.151. View

20.

Kile B, Viney E, Willson T, Brodnicki T, Cancilla M, Herlihy A . Cloning and characterization of the genes encoding the ankyrin repeat and SOCS box-containing proteins Asb-1, Asb-2, Asb-3 and Asb-4. Gene. 2000; 258(1-2):31-41. DOI: 10.1016/s0378-1119(00)00402-9. View